Research programme: liver disorders gene therapy - Synpromics /uniQure

Drug Profile

Research programme: liver disorders gene therapy - Synpromics /uniQure

Latest Information Update: 27 Apr 2015

Price : $50

At a glance

  • Originator uniQure
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Liver disorders

Most Recent Events

  • 01 Jan 2015 uniQure in-licenses synthetic promoter technology from Synpromics Limited
  • 01 Jan 2015 Early research in Liver disorders in Netherlands (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top